✦ LIBER ✦
A Multicenter, Prospective, Open Label, Historically Controlled Clinical Trial to Evaluate Efficacy and Safety in Primary Immunodeficiency Diseases (PID) Patients of Flebogamma®5% DIF, the Next Generation of Flebogamma®
✍ Scribed by Melvin Berger; The Flebogamma® 5% DIF Investigators
- Publisher
- Springer
- Year
- 2007
- Tongue
- English
- Weight
- 126 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0271-9142
No coin nor oath required. For personal study only.